Peter Nightingale - Biotron Company Secretary

BITRF Stock  USD 0.06  0.00  0.00%   

Executive

Mr. Peter James Nightingale was Company Secretary of Biotron Ltd since February 23, 1999. Mr. Nightingale graduated with a Bachelor of Economics degree from the University of Sydney and is a member of the Institute of Chartered Accountants in Australia. He has worked as achartered accountant in both Australia and the USA. As a director or company secretary Mr. Nightingale has, for more than 25 years, been responsible for the financial control, administration, secretarial and inhouse legal functions of a number of private and public listed companies in Australia, the USA and Europe including Bolnisi Gold N.L., Callabonna Uranium Limited, Mogul Mining N.L., Pangea Resources Limited, Perseverance Corporation Limited, Sumatra Copper Gold plc, Timberline Minerals, Inc. and Valdora Minerals N.L. Mr. Nightingale is currently a director of ASX listed Augur Resources Ltd, Cockatoo Coal Limited and Planet Gas Limited and unlisted public companies Equus Resources Limited and Nickel Mines Limited. since 1999.
Tenure 25 years
Phone61 2 9300 3344
Webhttps://www.biotron.com.au

Biotron Management Efficiency

The company has return on total asset (ROA) of (0.5574) % which means that it has lost $0.5574 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1224) %, meaning that it generated substantial loss on money invested by shareholders. Biotron's management efficiency ratios could be used to measure how well Biotron manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 77.24 K in total debt with debt to equity ratio (D/E) of 0.07, which may suggest the company is not taking enough advantage from borrowing. Biotron Limited has a current ratio of 2.3, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Biotron until it has trouble settling it off, either with new capital or with free cash flow. So, Biotron's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biotron Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biotron to invest in growth at high rates of return. When we think about Biotron's use of debt, we should always consider it together with cash and equity.
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia. Biotron operates under Biotechnology classification in the United States and is traded on OTC Exchange. Biotron Limited [BITRF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Biotron Limited Leadership Team

Elected by the shareholders, the Biotron's board of directors comprises two types of representatives: Biotron inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biotron. The board's role is to monitor Biotron's management team and ensure that shareholders' interests are well served. Biotron's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biotron's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Thomas, Independent Non-Executive Director
BSc GCertAppFin, MD Director
Peter Nightingale, Company Secretary
Michael Hoy, Independent Non-Executive Chairman of the Board
Michelle Miller, CEO, Managing Director, Executive Director
Stephen Locarnini, Director
CA BEcon, Company Sec
Denis Wade, Independent Non-Executive Director
Stephen MD, Chief Officer
Susan Pond, Independent Non-Executive Director

Biotron Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Biotron a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biotron in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biotron's short interest history, or implied volatility extrapolated from Biotron options trading.

Pair Trading with Biotron

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biotron position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biotron will appreciate offsetting losses from the drop in the long position's value.

Moving against Biotron Pink Sheet

  0.63NVO Novo Nordisk AS Financial Report 2nd of May 2024 PairCorr
  0.63NONOF Novo Nordisk ASPairCorr
  0.6AXP American Express Earnings Call TodayPairCorr
  0.5NSFDF NXT Energy SolutionsPairCorr
  0.47REGN Regeneron Pharmaceuticals Financial Report 2nd of May 2024 PairCorr
The ability to find closely correlated positions to Biotron could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biotron when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biotron - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biotron Limited to buy it.
The correlation of Biotron is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biotron moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biotron Limited moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biotron can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biotron Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Complementary Tools for Biotron Pink Sheet analysis

When running Biotron's price analysis, check to measure Biotron's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotron is operating at the current time. Most of Biotron's value examination focuses on studying past and present price action to predict the probability of Biotron's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotron's price. Additionally, you may evaluate how the addition of Biotron to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Please note, there is a significant difference between Biotron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biotron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biotron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.